Evotec SE (NASDAQ:EVO) Sees Large Increase in Short Interest

Evotec SE (NASDAQ:EVO) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 449,700 shares, a growth of 104.3% from the October 31st total of 220,100 shares. Based on an average trading volume of 195,200 shares, the days-to-cover ratio is presently 2.3 days. Currently, 0.2% of the shares of the stock are short sold.

Hedge Funds Weigh In On Evotec

A number of institutional investors have recently bought and sold shares of the business. Cetera Advisors LLC bought a new stake in shares of Evotec during the 1st quarter worth $188,000. Vanguard Personalized Indexing Management LLC acquired a new position in Evotec during the 2nd quarter worth approximately $87,000. DCF Advisers LLC lifted its stake in Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after purchasing an additional 67,156 shares during the last quarter. Novo Holdings A S bought a new position in shares of Evotec in the 2nd quarter valued at $71,183,000. Finally, Mediolanum International Funds Ltd acquired a new position in shares of Evotec in the third quarter valued at approximately $512,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Jefferies Financial Group lowered Evotec from a “buy” rating to a “hold” rating and dropped their price target for the stock from $8.70 to $3.80 in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft lowered Evotec from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Evotec in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $5.93.

Evotec Price Performance

EVO traded down $0.14 on Friday, hitting $4.69. 64,435 shares of the company were exchanged, compared to its average volume of 134,065. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The stock’s fifty day moving average is $3.95 and its 200-day moving average is $4.19. Evotec has a 12 month low of $2.85 and a 12 month high of $12.00.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.